Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
evobrutinib
- Development stage
- Phase 2
- Lead developer
- Merck
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Evobrutinib is an oral small molecule drug that acts as a highly selective inhibitor of Bruton’s tyrosine kinase (BTK). It was developed for the treatment of relapsing forms of multiple sclerosis (RMS) and other autoimmune diseases. By inhibiting BTK, evobrutinib reduces the activation and function of B cells and modulates macrophage/microglia activity, thereby decreasing inflammation in the central nervous system. Evobrutinib demonstrated promising results in early-phase clinical trials but failed to meet primary efficacy endpoints in phase III studies for RMS. The drug is not approved for any indication as of July 2024[3][5][6][8][9].
- Other names
- evobrutinib
02
Targets
BTK (Bruton tyrosine kinase)
Beyond the preview
Go deeper on evobrutinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on evobrutinib.